Safety Study Extension of Iloprost Power 15 in Pulmonary Arterial Hypertension
Status:
Completed
Trial end date:
2010-06-01
Target enrollment:
Participant gender:
Summary
Patients with symptomatic idiopathic (IPAH) or familial (FPAH) pulmonary arterial
hypertension in New York Heart Association (NYHA) class II to IV , naive to PAH treatment or
currently being treated with a stable dose of either bosentan or sildenafil and who complete
PROWESS 15 will be enrolled in the PROWESS 15 Extension study. This is a double-blind (12
week), randomized study to compare the safety and tolerability of inhaled iloprost power
disc-15 and power disc-6 in patients with symptomatic pulmonary arterial hypertension (PAH).
After completion of the double blind period, patients will be entered in the open label
period using iloprost power disc-15.